CLL

>

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Latest News

FDA Approval: Developing story
FDA Approves Breyanzi for Relapsed/Refractory CLL/SLL

March 15th 2024

Breyanzi has been approved by the FDA for some previously treated patients with leukemia — marking the first CAR-T cell therapy approved for this patient population.

Image of a pill split in half with graphics of circles in the middle, symbolizing technology.
FDA Approves Easier-to-Swallow Imbruvica Formulation

February 29th 2024

A medical professional holding a vial of a BTK inhibitor with a syringe for patients with blood cancer.
Drug Combos May Help Lower Blood Pressure in Patients Taking Imbruvica

February 6th 2024

blood cancer cells floating. A novel CD NK therapy could benefit patients with lymphoma, CLL, SLL, mantle cell lymphoma, among others.
Cord Blood-Derived Treatment Shows Promise in Blood Cancer

January 25th 2024

NX-5948, a BTK degrader, was granted Fast Track designation by the FDA for patients with R/R CLL and R/R SLL.
FDA Grants NX-5948 Fast Track Designation for R/R CLL, SLL

January 18th 2024

Video Series
Video Interviews
Podcasts
CURE Talks Cancer podcast
Understanding the Pendulum Swing in CLL Research Over the Last Decade

More News